Literature DB >> 7689443

Impact of the fluoroquinolones on gastrointestinal flora.

V Korten1, B E Murray.   

Abstract

A number of studies have been performed to evaluate the effect of the fluoroquinolones on gastrointestinal flora. The fluoroquinolones have only slight or no effect on the oropharyngeal flora, except when Neisseria, Haemophilus or Branhamella spp. are present. Studies have consistently shown that Gram-negative facultative bacteria of the lower intestinal flora are strongly suppressed during administration of these agents. Total faecal anaerobes are generally unchanged. The effect of the fluoroquinolones on Gram-positive bacteria is more variable with mild to moderate suppression reported with some agents. In view of the high faecal concentrations of the fluoroquinolones, the general lack of effect on anaerobes is surprising; it may be attributable to the large number of microorganisms found in faeces and faecal binding of the fluoroquinolones. Several recent studies suggest that the effects of some fluoroquinolones on faecal anaerobes and Gram-positive cocci may be more profound in certain patient populations such as bone marrow transplant recipients and patients undergoing gastrointestinal surgery. Colonisation with yeasts and the emergence of resistant bacterial strains have been reported during or after fluoroquinolone administration in some studies. Future studies will need to investigate the effect of the newer agents with greater activity against anaerobes and Gram-positive cocci on the gastrointestinal flora and to continue surveillance for resistant organisms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689443     DOI: 10.2165/00003495-199300453-00021

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  69 in total

1.  [Effect of sparfloxacin on fecal microflora and its fecal concentration in patients with bacillary dysentery].

Authors:  H Sagara; T Tsunoda; Y Nitta
Journal:  Kansenshogaku Zasshi       Date:  1991-09

2.  CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.

Authors:  P C Fuchs; A L Barry; R N Jones; C Thornsberry; L W Ayers; T L Gavan; E H Gerlach
Journal:  Diagn Microbiol Infect Dis       Date:  1987-03       Impact factor: 2.803

3.  Inactivation of quinolone by feces.

Authors:  J J van Saene; H K van Saene; C F Lerk
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

4.  Prevention of infections in neutropenic patients with pefloxacin.

Authors:  F Meunier
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

Review 5.  Suppression of the oropharyngeal and gastrointestinal microflora by ciprofloxacin: microbiological and clinical consequences.

Authors:  C Edlund; C E Nord
Journal:  Scand J Infect Dis Suppl       Date:  1989

6.  Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.

Authors:  M Rozenberg-Arska; A W Dekker; J Verhoef
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

7.  Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.

Authors:  P M Shah; A Sammann; V Schäfer; M Seczendi; H Knothe
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

8.  Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.

Authors:  R Paganoni; C Herzog; A Braunsteiner; P Hohl
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

9.  Ofloxacin for prevention of bacterial infections in granulocytopenic patients.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

10.  Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin.

Authors:  B E Scully; K Jules; N X Chin; H C Neu
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

View more
  7 in total

Review 1.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients.

Authors:  Kenneth M Wener; Vered Schechner; Howard S Gold; Sharon B Wright; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

Review 3.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

4.  Absorption of ofloxacin isomers in the rat small intestine.

Authors:  L Rabbaa; S Dautrey; N Colas-Linhart; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 5.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 6.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 7.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.